Abstract
Optimal biochemical control cannot be attained by long-acting somatostatin analog monotherapy in a large proportion of patients with acromegaly. Such therapy might result in increased mortality, poor control of signs and symptoms of disease and decreased quality of life. Combination treatment with somatostatin analogs and pegvisomant (a growth-hormone-receptor antagonist) is, however, highly effective at normalizing the level of insulin-like growth factor I in over 90% of patients and might also have a favorable effect on quality of life in those with biochemically controlled acromegaly. Moreover, whereas pegvisomant monotherapy does not lead to a decrease in the size of the pituitary tumor, combination therapy with somatostatin analogs results in a clinically relevant decrease in tumor size in about 20% of patients. The main adverse effects of combination treatment are transient elevations in the levels of transaminases, which occur in about 15% of patients, especially in those with diabetes mellitus. In this Review, we discuss the available data on the long-term efficacy and safety of somatostatin analog–pegvisomant combination treatment and its potential use in patients with acromegaly.
Key Points
-
Combination therapy for acromegaly with somatostatin analogs and pegvisomant has at least the same efficacy as pegvisomant alone, but enables reduced doses of pegvisomant to be used
-
Control of tumor size is established in all patients in response to combination therapy, and some tumors even decrease in size
-
Combination therapy seems to improve quality of life in patients who have already achieved biochemical control of acromegaly in response to monotherapy with somatostatin analogs
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558–2573 (2006).
Bates, P. R., Carson, M. N., Trainer, P. J., Wass, J. A. & UK National Acromegaly Register Study Group (UKAR-2). Wide variation in surgical outcomes for acromegaly in the UK. Clin. Endocrinol. (Oxf.) 68, 136–142 (2008).
Holdaway, I. M. Treatment of acromegaly. Horm. Res. 62 (Suppl. 3), 79–92 (2004).
Feenstra, J. et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365, 1644–1646 (2005).
Neggers, S. J., de Herder, W. W., Janssen, J. A., Feelders, R. A. & van der Lely, A. J. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160, 529–533 (2009).
Neggers, S. J. et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92, 4598–4601 (2007).
van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001).
Higham, C., Chung, T., Lawrance, J., Drake, W. & Trainer, P. Long term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) doi:10.1111/j.1365–22652008.03469.x.
Biering, H. et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol. 154, 213–220 (2006).
Jørgensen, J. O. et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90, 5627–5631 (2005).
Harris, P. E. Treatment with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR, in acromegaly [OR53–3]. Presented at The Endocrine Society 89th Annual Meeting.
Neggers, S. J. et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93, 3853–3859 (2008).
Kopchick, J. J., Parkinson, C., Stevens, E. C. & Trainer, P. J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623–646 (2002).
Clark, R. et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271, 21969–21977 (1996).
Drake, W. M., Parkinson, C., Besser, G. M. & Trainer, P. J. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol. Metab. 12, 408–413 (2001).
van der Lely, A. J. et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86, 478–481 (2001).
Leung, K. C., Doyle, N., Ballesteros, M., Waters, M. J. & Ho, K. K. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712–4720 (2000).
Murray, R. D. et al. Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis. J. Clin. Invest. 114, 349–356 (2004).
Wurzburger, M. I., Prelevic, G. M., Sönksen, P. H., Balint-Peric, L. A. & Wheeler, M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J. Clin. Endocrinol. Metab. 77, 267–272 (1993).
Shishko, P. I., Dreval, A. V., Abugova, I. A., Zajarny, I. U. & Goncharov, V. C. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res. Clin. Pract. 25, 1–12 (1994).
Petrossians, P. et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005).
Parkinson, C. et al. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J. Clin. Endocrinol. Metab. 87, 1797–1804 (2002).
De Marinis, L. et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10, 227–232 (2007).
Beauregard, C., Truong, U., Hardy, J. & Serri, O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. (Oxf.) 58, 86–91 (2003).
Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89–95 (2008).
Holdaway, I. M., Rajasoorya, C. R., Gamble, G. D. & Stewart, A. W. Long-term treatment outcome in acromegaly. Growth Horm. IGF Res. 13, 185–192 (2003).
Holdaway, I. M., Rajasoorya, R. C. & Gamble, G. D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004).
Swearingen, B. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419–3426 (1998).
Hua, S. C., Yan, Y. H. & Chang, T. C. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur. J. Endocrinol. 155, 831–837 (2006).
Biermasz, N. R., Pereira, A. M., Smit, J. W., Romijn, J. A. & Roelfsema, F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90, 2731–2739 (2005).
Biermasz, N. R. et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J. Clin. Endocrinol. Metab. 89, 5369–5376 (2004).
Bonapart, T. I. et al. The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur. J. Endocrinol. 152, 217–224 (2005).
Webb, S. M. et al. Acromegaly Quality of Life Questionnaire (AcroQoL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin. Endocrinol. (Oxf.) 57, 251–258 (2002).
Schreiber, I. et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156, 75–82 (2007).
Shi, Y. F., Zhu, X. F., Harris, A. G., Zhang, J. X. & Dai, Q. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J. Clin. Endocrinol. Metab. 76, 32–37 (1993).
Feenstra, J., van Aken, M. O., de Herder, W. W., Feelders, R. A. & van der Lely, A. J. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur. J. Endocrinol. 154, 805–806 (2006).
Bonert, V. S. et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J. Clin. Endocrinol. Metab. 93, 3515–3518 (2008).
Maffei, P., Martini, C., Pagano, C., Sicolo, N. & Corbetti, F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann. Intern. Med. 145, 310–312 (2006).
Hodish, I. & Barkan, A. Long-term effects of pegvisomant in patients with acromegaly. Nat. Clin. Pract. Endocrinol. Metab. 4, 324–332 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. J. van der Lely is a consultant for Ipsen Pharma International, Novartis Pharma and Pfizer International; he has received travel support from Novartis Pharma and Pfizer International.
S. J. C Neggers declares no competing interests.
Rights and permissions
About this article
Cite this article
Neggers, S., van der Lely, A. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 5, 546–552 (2009). https://doi.org/10.1038/nrendo.2009.175
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.175
This article is cited by
-
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Endocrine (2021)
-
Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly
Endocrine (2015)
-
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Pituitary (2011)
-
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR
Pituitary (2011)